

APCCC Detailed Programme 2022 (updated on 6 <sup>th</sup> of March 2022 – Subject to minor changes)			
Thursday 28 <sup>th</sup> April 2022			
<b>Time</b>	<b>Welcome</b>		
09:00	APCCC 2022	Silke Gillessen Aurelius Omlin	7 Minutes
	What is important from a patient's perspective?	David Matheson	8 Minutes
9:15 – 11:00 <b>Session 1</b>	High-risk and locally advanced prostate cancer	Chairs: Neha Vapiwala and Bertrand Tombal	<b>Duration</b>
	Impact of next-generation imaging : What is the optimal (current) tracer for PET-based imaging for staging	Ken Herrmann	10 min
Are we ready to change management based on next-generation imaging?			
	• Yes	Jason Efstathiou	10 min
	• No	Nicolas Mottet	10 min
	Impact of histology variants (ductal/intraductal/ciribriform) on treatment recommendation	Declan Murphy	10 min
	Management of cN1 prostate cancer (including systemic therapy)	Darren Poon	10 min
	Management of pN1 disease (including systemic therapy)	Derya Tilki	10 min
Q&A (15 min)			
Discussion of APCCC 2022 voting results (30 min)			
11:00 – 11:30	COFFEE BREAK		
11:30 – 13:15 <b>Session 2</b>	Biochemical recurrence	Chairs: Neal Shore and Almudena Zapatero	<b>Duration</b>
	Who needs early salvage RT and who needs adjuvant RT in 2022?	Kosj Yamoah	10 min
	Who needs systemic treatment with salvage RT?	Brandon Mahal	10 min
	Biochemical recurrence after definitive radiotherapy of the prostate – what are the local treatment options?	Jochen Walz	10 min
Debate			
	• Imaging directed treatment for BCR	Nick James	10 min
	• PSA directed treatment for BCR	Neha Vapiwala	10 min
	How can treatment be individualised by using genomic classifiers?	Felix Feng	10 min
Q&A (15 min)			
Discussion of APCCC 2022 voting results (30 min)			
13:15 – 14:15	LUNCH		
14:15– 15:35 <b>Session 3 part 1</b>	Management of metastatic hormone-sensitive prostate cancer (mHSPC)	Chairs: Matthew Smith and Silke Gillessen	<b>Duration</b>
mHSPC: Do we need more granularity?			
	• Systemic treatment options for the different subgroups	Mary Ellen Taplin	10 min
	• Can biology help for treatment decisions?	Gert Attard	10 min
When low-volume on conventional imaging goes into high-volume on next-generation imaging in mHSPC			
	How frequent is this situation?	Michael Hofman	8 min
	• Treat like low-volume	Karim Fizazi	8 min

• Treat like high-volume		Ian Davis	8 min
Treatment intensification strategies in mHSPC: Triplets and more		Chris Sweeney	10 min
Treatment de-escalation strategies in mHSPC		Bertrand Tombal	10 min
Q&A (15 min)			
15:35 – 16:05		COFFEE BREAK	
16:05 – 17:40 <b>Session 3</b> <b>part 2</b>	Management of metastatic hormone-sensitive prostate cancer (mHSPC)	Chairs: Matthew Smith and Silke Gillessen	Duration
Which patients need treatment of the primary tumour in mHSPC and when and how to deliver treatment?		Alberto Bossi	12 min
Treatment of vulnerable/frail patients with mHSPC		Alicia Morgans	12 min
Optimal treatment for mHSPC from a health economics standpoint		Caroline Clarke	12 min
Uptake of new treatment options for mHSPC in real life – education, access, use and diversity		Andrew Armstrong	12 min
Q&A (15 min)			
Discussion of APCCC 2022 voting results (30 min)			
17:45 Networking Aperitivo			

Friday 29 <sup>th</sup> April 2022			
<b>Extra session</b> 08:00 – 08:30	Movember Session	Chair: Jane Fisher	Duration
Update on IRONMAN Project		Dan George	20 min
Discussion (10 min)			
08:30 – 10:10 <b>Session 4</b>	Management of non-metastatic CRPC	Chairs: Maha Hussain and Elena Castro	Duration
Overview of treatment options		Eleni Efstathiou	12 min
Advantages of using novel imaging in nmCRPC		Michael Morris	10 min
Disadvantages of using novel imaging in nmCRPC		Alberto Briganti	10 min
Genomic and clinical markers in nmCRPC		Joaquin Mateo	10 min
Treatment of the primary or of local relapse in nmCRPC		Pierre Blanchard	10 min
Q&A (15 min)			
Discussion of APCCC 2022 voting results (30 min)			
10:10 – 10:40		COFFEE BREAK	
10:40 – 12:15 <b>Session 5</b>	Importance of lifestyle and prevention of complications in advanced prostate cancer	Chairs: Alicia Morgans and Noel Clarke	Duration
How to take care of the bones?		Oliver Sartor	12 min
How to take care of the heart?		Fred Saad	12 min
How to take care of muscle strength?		Heather Cheng	12 min
How to take care of brain and mood?		Chuck Ryan	12 min
Q&A (15 min)			
Discussion of APCCC 2022 voting results (30 min)			
12:15 – 13:15		LUNCH	
13:15 - 14:45 <b>Session 6</b> <b>part 1</b>	Management of metastatic CRPC	Chairs: Johann de Bono and Heather Cheng	Duration
Lutetium-PSMA therapy		Matthew Smith	10 min

Is there still a role for radium-223?		Neal Shore	10 min
Optimal treatment sequencing in mCRPC		Maha Hussain	15 min
Debate PARP inhibitors in mCRPC			
• PARP inhibitors for all mCRPC patients		Noel Clarke	10 min
• PARP inhibitors only in selected mCRPC patients		Johann de Bono	10 min
Tumour genomic profiling: What is relevant and how to avoid potential pitfalls?		Colin Pritchard	15 min
Q&A (15 min)			
14:45 – 15:15		COFFEE BREAK	
15:15 – 17:00 Session 6 part 2	Management of metastatic CRPC	Chairs: Johann de Bono and Heather Cheng	Duration
How to read a genomic testing report		Kim Chi	12 min
Update on immune checkpoint inhibitors		Emmanuel Antonarakis	12 min
Aggressive variant prostate cancer: Definition, diagnosis, treatment		Eric Small	15 min
Risk-adapted treatment monitoring in mCRPC		Anwar Padhani	12 min
Q&A (15 min)			
Discussion of APCCC 2022 voting results (30 min)			
17:00 End of Day 2			

Saturday 30 <sup>th</sup> of April 2022			
09:00 – 09:50 Session 7 part 1	Oligometastatic and oligoprogressive prostate cancer	Chairs: Joe O'Sullivan and Mary-Ellen Taplin	Duration
What is the evidence of MDT in synchronous vs metachronous mHSPC?		Daniel Spratt	12 min
What is the evidence of systemic therapies (alone or in combination with MDT) in oligometastatic mHSPC?		Mary-Ellen Taplin	12 min
Are there predictors for successful treatment of oligometastatic prostate cancer?		Piet Ost	12 min
Q&A (15 min)			
09:50 - 10:10		COFFEE BREAK	
10:10 – 11:30 Session 7 part 2	Oligometastatic and oligoprogressive prostate cancer	Chairs: Joe O'Sullivan and Mary-Ellen Taplin	Duration
How to interpret and confirm lesions positive on PSMA PET but with no correlate on CT?		Stefano Fanti	12 min
How to follow-up patients who had PSMA PET as baseline imaging?		Tom Beer	12 min
Does “oligoprogressive” prostate cancer exist as a distinct clinically meaningful entity and if yes, how to treat it?		Rob Jones	12 min
Q&A (15 min)			
Discussion of APCCC 2022 voting results (30 min)			
11:30 Closing Remarks: Silke Gillissen and Aurelius Omlin			